Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Business

Business

Price of Overdose Treatment Soared 680% in Last 3 Years

Over the last few years, the price of an emergency medication commonly referred to as an “antidote” for opioid overdoses has skyrocketed. The device, Evizio, is the only auto-injector of nalaxone.

Nalaxone counteracts the effect of opioid overdoses by preventing the drug from interacting with the brain’s receptors. Evzio manufacturer Kaleo also owns Auvi-Q, the emergency epinephrine device recently brought back as a competitor to the EpiPen in the U.S.

Evzio has been on the market since 1971, though it was only approved in the U.S. in 2014. Initially, the list price was $575 for a two-pack. Now, the price a two-pack has soared to $4,500, an increase of 680%.

The Auvi-Q and Evzio use the same technology in their auto-injector mechanism to deliver their respective emergency treatments. The list price for a two-pack of Auvi-Q is also $4,500, though Kaleo states the cash price for patients without insurance is $360. The company also holds that more than 200 million people will be able to get the auto-injector of epinephrine with a $0 copay. Still, the list price is roughly 640% more than the list price of the EpiPen, which has come under fire recently for increasing the price of a two-pack by 500% over a period of seven years.

The pricing of Evzio and Auvi-Q have caught the attention of Democratic Minnesota Senator Amy Klobuchar, who sent a letter to Kaleo on Friday asking for details about the company’s pricing strategy.

Mark Herzog, vice president of corporate affairs at Kaleo, told BusinessInsider in a statement, “When setting the ‘list’ price for products, kaléo always starts with the needs of the patient first and then engages with multiple stakeholders in the healthcare system.”

“Following these discussions, in order to help insure our product is available as an option to most patients for $0 out-of-pocket, we set the list price at $4500,” he continued.

This rationale did not satisfy Senator Klocuchar, who wrote in reply,” While these subsidies and programs are noteworthy, I am concerned that they do not address the underlying problem of rising prescription drug costs.”


Comment Template

You May Also Like

Business

Pfizer, the largest drugmaker in the world, is planning to divest their off-patent drug business and to combine it with Mylan, a generic-drug maker....

Business

The Food and Drug Administration (FDA) recently issued warnings to two companies – North Carolina-based KratomNC and California-based Cali Botanicals – for making illegal...

Not Sure

The Food and Drug Administration (FDA) is looking into changing the rules for the manufacturing of opioids by making the drugs less addictive. The...

Politics

Opioid death crisis linked to OxyContin? The state of Minnesota is suing pharmaceutical manufacturer Purdue Pharma for its marketing of narcotic OxyContin. Attorney General...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok